# MAX - SHOCK Clinical Trial

Study · id `cardio:ct-nct06556667` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06556667](<https://clinicaltrials.gov/study/NCT06556667>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06556667

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 376 participants.

## Technical summary

Registry record NCT06556667. Randomized; single masking; primary purpose treatment. Start 2025-03-31 (actual); primary completion 2027-09-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 376 participants (planned count; ClinicalTrials.gov record NCT06556667, source copy `cardio:ctgov-nct06556667-2026-02-03`, retrieved 2026-10-26)
- Started: 2025-03-31 (actual) (ClinicalTrials.gov record NCT06556667, source copy `cardio:ctgov-nct06556667-2026-02-03`, retrieved 2026-10-26)
- Primary completion: 2027-09-01 (anticipated) (ClinicalTrials.gov record NCT06556667, source copy `cardio:ctgov-nct06556667-2026-02-03`, retrieved 2026-10-26)
- Completion: 2027-09-01 (anticipated) (ClinicalTrials.gov record NCT06556667, source copy `cardio:ctgov-nct06556667-2026-02-03`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT06556667, source copy `cardio:ctgov-nct06556667-2026-02-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06556667-2026-02-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: MAX - SHOCK Clinical Trial
- Acronym: MAX-SHOCK
- Condition: Cardioversion
- Condition: Atrial Fibrillation
- Intervention (Device): biphasic defibrillator with maximum energy of 200J (® Zoll)
- Intervention (Device): biphasic defibrillator with maximum energy of 360J (® Physio-Control)
- Lead sponsor: Ottawa Heart Institute Research Corporation
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Ottawa Heart Institute Research Corporation (`cardio:org-ottawa-heart-institute-research-corporation`)

## Provenance

Content hash: 99f34167040d77a9158ee622d3966a3d53e1d76de429d4a2468cd52e13464a96
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
